Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials

Fig. 3

Efficacy of mepolizumab, by allergen sensitivity. A Change from baseline to study end in pre-bronchodilator FEV1 per season; B Change from baseline to study end in SGRQ total score per season; C Change from baseline to study end in ACQ-5 score per season. All plots are for patients receiving mepolizumab versus placebo. ACQ Asthma Control Questionnaire, CI confidence interval, FEV1 forced expiratory volume in 1 s, SGRQ St George’s Respiratory Questionnaire

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us